Qulipta

(atogepant)
QULIPTA 10 MG Oral TabletQULIPTA 30 MG Oral Tablet
View 1 more
NO BLACK BOX WARNING

Dosage & administration

drug label

Qulipta prescribing information

samples

Request Qulipta samples

PDF
Sample Online Form
Learn More

prior authorization

Qulipta prior authorization resources

Most recent Qulipta prior authorization forms

View By Payer
Updated: Jun 04, 2023Highmark BCBS Western PA - CGRP Inhibitors Prior Authorization Form
Updated: Jun 01, 2023Sooner Care - Qulipta Prior Authorization Form
Updated: May 31, 2023Blue Cross Blue Shield of North Carolina - Migraine Calcitonin Agents Prior Authorization Form

OTHER
Complete Letter of Medical Necessity

OTHER
Coverage Authorization Appeals
Learn More

financial assistance

Qulipta financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
Learn More

patient education

Qulipta patient education

Getting started on Qulipta

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

BRAND PAGE
About Qulipta
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

VIDEO
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHER
Doctor Discussion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDF
Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

Other resources

Learn More

people also ask

Qulipta FAQs

Is QULIPTA safe to use during pregnancy?There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women. In animal studies, oral administration of atogepant during the period of organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse developmental effects (decreased fetal and offspring body weight in rats; increased incidence of fetal structural variations in rabbits) at exposures greater than those used clinically. Women who are pregnant or planning to become pregnant should consult with their healthcare provider to determine the best treatment option for their migraine.
Is QULIPTA safe to use during lactation?There are no data on the presence of atogepant in human milk, the effects of atogepant on the breastfed infant, or the effects of atogepant on milk production. In lactating rats, oral dosing with atogepant resulted in levels of atogepant in milk approximately 2-fold higher than that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QULIPTA and any potential adverse effects on the breastfed infant from QULIPTA or from the underlying maternal condition.
Is QULIPTA safe to use in pediatric patients?Safety and effectiveness in pediatric patients have not been established. QULIPTA is not recommended for use in pediatric patients.
Is QULIPTA safe to use in elderly patients?Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. Clinical studies of QULIPTA did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Is QULIPTA safe to use in patients with hepatic impairment?No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic impairment. Avoid use of QULIPTA in patients with severe hepatic impairment.
Is QULIPTA safe to use in patients with renal impairment?The renal route of elimination plays a minor role in the clearance of atogepant. No dose adjustment is recommended for patients with mild or moderate renal impairment.
FAQ Data Source